Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

By Slepushkin V.A.   Katz J.M.   Black R.A.   Gamble W.C.   Rota P.A.   Cox N.J.  

Vaccine, Vol. 13, Iss. 15, 1995-01 ,pp. : 1399-1402

Elsevier

Access to resources Recommend Favorite

An inactivated bovine virus diarrhoea virus (BVDV) type 1 vaccine affords clinical protection against BVDV type 2

By Makoschey B.   Janssen M.G.J.   Vrijenhoek M.P.   Korsten J.H.M.   Marel P.v.d.  

Vaccine, Vol. 19, Iss. 23, 2001-04 ,pp. : 3261-3268

Elsevier

Access to resources Recommend Favorite

Therapeutic vaccination against HSV-2: influence of vaccine formulation on immune responses and protection in mice

By Mohamedi S.A.   Heath A.W.   Jennings R.  

Vaccine, Vol. 18, Iss. 17, 2000-03 ,pp. : 1778-1792

Elsevier

Access to resources Recommend Favorite

Cytotoxicity and Genotoxicity of Diallyl Sulfide and Diallyl Disulfide Towards Chinese Hamster Ovary Cells

By Musk S.R.R.   Clapham P.   Johnson I.T.  

Food and Chemical Toxicology, Vol. 35, Iss. 3, 1997-03 ,pp. : 379-385

Elsevier

Access to resources Recommend Favorite

Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell&unknown; 2 vaccine

By Harbour D.A.   Gunn-Moore D.A.   Gruffydd-Jones T.J.   Caney S.M.A.   Bradshaw J.   Jarrett O.   Wiseman A.  

Vaccine, Vol. 20, Iss. 23, 2002-07 ,pp. : 2866-2872

Elsevier

Access to resources Recommend Favorite